Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

被引：2
|
作者：
Desai, Jayesh
Voskoboynik, Mark
Markman, Ben
Hou, Jeannie
Zeng, Dewan
Meniawy, Tarek
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Nucleus Network, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Monash Univ, Melbourne, Vic, Australia
[6] BeiGene USA Inc, Emeryville, CA USA
[7] Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS3113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3113
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
    Murakami, Haruyasu
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Fujiwara, Yutaka
    Mizugaki, Hidenori
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [32] Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti-PD-1 monoclonal antibody, in patients (pts) with advanced solid tumors
    Sachdev, J. C.
    Patnaik, A.
    Waypa, J.
    Pelusi, J.
    Beeram, M.
    Im, E.
    Jenkins, D.
    McEachern, K.
    Lu, S.
    Guo, W.
    Tran, R.
    Reichert, V.
    Bobilev, D.
    Kansra, V.
    Weiss, G. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
    Ching-Liang Ho
    Tsu-Yi Chao
    Chia-Lun Chang
    Hsuan-Yu Lin
    BioDrugs, 2024, 38 : 287 - 299
  • [34] Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia-Lun
    Lin, Hsuan-Yu
    BIODRUGS, 2024, 38 (02) : 287 - 299
  • [35] PHASE 1 TRIAL OF FIRST-IN-CLASS ANTI-CD96 MONOCLONAL ANTIBODY INHIBITOR, GSK6097608, MONOTHERAPY AND COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY, DOSTARLIMAB, IN ADVANCED SOLID TUMORS
    Hamid, Omid
    Baxter, Dawn
    Easton, Rachael
    Siu, Lilian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A518 - A518
  • [36] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
    Patnaik, Amita
    Weiss, Glen J.
    Rasco, Drew W.
    Blaydorn, Lisa
    Mirabella, Amy
    Beeram, Murali
    Guo, Wei
    Lu, Sharon
    Danaee, Hadi
    McEachern, Kristen
    Im, Ellie
    Sachdev, Jasgit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
  • [37] A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
    Di Giacomo, A. M.
    Schenker, M.
    Medioni, J.
    Mandziuk, S.
    Majem, M.
    Gravis, G.
    Cornfeld, M.
    Ranganathan, S.
    Lou, S.
    Csoszi, T.
    ESMO OPEN, 2024, 9 (03)
  • [38] Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors
    Roda, Desamparados
    Zugazagoitia, Jon
    Garralda, Elena
    Spira, Alexander I.
    El-Khoueiry, Anthony B.
    Babiker, Hani M.
    Oppelt, Peter John
    Lin, Xi
    Xie, Shaozhen
    Chen, Margaret E.
    Gan, Jinping
    Wong, Gabrielle
    Pollard, Jack Russella
    Hedrich, William
    Pallante, John
    Hatzis, Christos
    Andtbacka, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer
    Oaknin, Ana
    Tinker, Anna, V
    Gilbert, Lucy
    Samouelian, Vanessa
    Mathews, Cara
    Brown, Jubilee
    Barretina-Ginesta, Maria-Pilar
    Moreno, Victor
    Gravina, Adriano
    Abdeddaim, Cyril
    Banerjee, Susana
    Guo, Wei
    Danaee, Hadi
    Im, Ellie
    Sabatier, Renaud
    FUTURE ONCOLOGY, 2021, 17 (29) : 3781 - 3785
  • [40] AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas, Sophia
    Meniawy, Tarek
    Kao, Steven Chuan-Hao
    Wang, Ruihua
    Zuo, Yunxia
    Zheng, Hao
    Tan, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345